Skip to main content

Table 2 Patients' demographic and clinical characteristics according to mitochondrial DNA haplogroup

From: Survival and mitochondrial function in septic patients according to mitochondrial DNA haplogroup

  Haplogroup  
  HV (n = 44) U (n = 24) JT ( n = 15) No R ( n = 13) P value
Gender, male 28 (63.6) 17 (70.8) 8 (53.3) 7 (53.8) 0.64
Age (years) 57 (46 to 65) 62 (52 to 74) 64 (54 to 81) 50 (39 to 66) 0.06
Diabetes mellitus 21 (47.7) 9 (37.5) 4 (26.7) 2 (15.4) 0.14
COPD 5 (11.4) 3 (12.5) 1 (6.7) 1 (7.7) 0.92
Ischemic heart disease 3 (6.8) 2 (8.3) 1 (6.7) 1 (7.7) 0.99
Ischemic stroke 2 (4.5) 1 (4.2) 0 0 0.73
Site of infection      0.97
   Respiratory 31 (70.5) 16 (66.7) 8 (53.3) 7 (53.8)  
   Abdominal 8 (18.2) 4 (16.7) 5 (33.3) 4 (30.8)  
   Urinary 1 (2.3) 1 (4.2) 1 (6.7) 1 (7.7)  
   Skin 2 (4.5) 2 (8.3) 1 (6.7) 1 (7.7)  
   Endocarditis 1 (2.3) 1 (4.2) 0 0  
   Others 1 (2.3) 0 0 0  
Microorganism responsible      
   Unknown 23 (52.3) 13 (54.2) 6 (40.0) 7 (53.8) 0.83
   Gram-positive 11 (25.0) 6 (25.0) 5 (33.3) 2 (15.4) 0.75
   Gram-negative 9 (20.5) 5 (20.8) 4 (26.7) 4 (30.8) 0.85
   Fungi 3 (6.8) 1 (4.2) 0 0 0.62
   Anaerobe 1 (0.8) 0 0 0 0.78
Bloodstream infection 5 (11.4) 3 (12.5) 3 (20.0) 2 (15.4) 0.86
Empiric antimicrobial treatment      0.99
   Unknown if adequate due to negative cultures 23 (52.3) 12 (50.0) 7 (46.7) 7 (53.8)  
   Adequate 17 (38.6) 10 (41.7) 6 (40.0) 5 (38.5)  
   Unknown if adequate due to diagnosis by antigenuria 3 (6.8) 2 (8.3) 2 (13.3) 1 (7.7)  
   Inadequate 1 (2.3) 0 0 0  
β-lactamic more aminoglycoside 10 (22.7) 5 (20.8) 3 (20.0) 2 (15.4) 0.95
β-lactamic more quinolone 25 (56.8) 14 (58.3) 6 (40.0) 7 (53.8) 0.68
Mean blood pressure (mmHg) 68 (63 to 71) 66 (63 to 71) 69 (63 to 75) 69 (63 to 72) 0.63
Septic shock 38 (86.4) 21 (87.5) 13 (86.7) 11 (84.6) 0.99
Norepinephrine 38 (86.4) 21 (87.5) 13 (86.7) 11 (84.6) 0.99
Norepinephrine dose (μg/kg/minute) 0.5 (0.3 to 0.8) 0.5 (0.3 to 0.7) 0.5 (0.4 to 0.9) 0.5 (0.3 to 1.0) 0.77
Dobutamine 3 (6.8) 2 (8.3) 1 (6.7) 1 (7.7) 0.99
Dobutamine dose (μg/kg/minute) 6.0 (5.0 to 8.0) 6.0 (5.0 to 7.0) 5.0 8.0 0.56
PaO2/FIO2 ratio 199 (107 to 280) 152 (80 to 250) 138 (84 to 197) 128 (99 to 335) 0.38
Creatinine (mg/dl) 1.20 (0.80 to 2.06) 1.75 (1.00 to 2.17) 2.05 (1.10 to 3.07) 0.75 (0.47 to 1.42) 0.20
Bilirubin (mg/dl) 1.20 (0.64 to 2.30) 1.37 (0.88 to 2.56) 0.92 (0.48 to 1.44) 0.40 (0.17 to 0.66) 0.10
Leukocytes (×103/mm3) 12.2 (5.4 to 19.9) 10.2 (5.2 to 20.4) 16.4 (8.5 to 25.9) 13.8 (11.6 to 16.9) 0.81
Lactic acid (mmol/l) 2.35 (1.42 to 4.45) 3.20 (1.30 to 5.87) 3.80 (1.70 to 4.65) 1.30 (0.87 to 2.00) 0.048
Platelets (×103/mm3) 166 (86 to 224) 185 (78 to 312) 120 (43 to 193) 207 (103 to 294) 0.30
INR 1.42 (1.11 to 1.65) 1.38 (1.20 to 1.65) 1.24 (1.15 to 1.67) 1.21 (1.07 to 1.52) 0.63
aPTT (seconds) 33 (29 to 45) 35 (31 to 41) 36 (26 to 49) 30 (28 to 34) 0.40
APACHE II score 20 (16 to 25) 20 (14 to 24) 21 (18 to 23) 23 (14 to 29) 0.86
SOFA score 9 (7 to 12) 10 (9 to 14) 9 (8 to 12) 9 (6 to 11) 0.26
Survivors at 180 days 23 (52.3) 13 (54.2) 11 (73.3) 7 (53.8) 0.54
Survivors at 30 days 26 (59.1) 17 (70.8) 13 (86.7) 7 (53.8) 0.18
  1. Data presented as number (percentage) or median (interquartile range). COPD, chronic obstructive pulmonary disease; PaO2/FIO2, pressure of arterial oxygen/fraction inspired oxygen; aPTT, activated partial thromboplastin time; INR, International Normalized Ratio; APACHE, Acute Physiology and Chronic Health Evaluation; SOFA, Sepsis-related Organ Failure Assessment.